Cargando…

Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction

BACKGROUND: Barth syndrome is a rare, multisystem disorder caused by mutations in tafazzin that lead to cardiolipin deficiency and mitochondrial abnormalities. Patients most commonly develop an early-onset cardiomyopathy in infancy or fetal life. METHODS AND RESULTS: Knockdown of tafazzin (TAZKD) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Phoon, Colin K. L., Acehan, Devrim, Schlame, Michael, Stokes, David L., Edelman-Novemsky, Irit, Yu, Dawen, Xu, Yang, Viswanathan, Nitya, Ren, Mindong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487377/
https://www.ncbi.nlm.nih.gov/pubmed/23130124
http://dx.doi.org/10.1161/JAHA.111.000455
_version_ 1782248478740578304
author Phoon, Colin K. L.
Acehan, Devrim
Schlame, Michael
Stokes, David L.
Edelman-Novemsky, Irit
Yu, Dawen
Xu, Yang
Viswanathan, Nitya
Ren, Mindong
author_facet Phoon, Colin K. L.
Acehan, Devrim
Schlame, Michael
Stokes, David L.
Edelman-Novemsky, Irit
Yu, Dawen
Xu, Yang
Viswanathan, Nitya
Ren, Mindong
author_sort Phoon, Colin K. L.
collection PubMed
description BACKGROUND: Barth syndrome is a rare, multisystem disorder caused by mutations in tafazzin that lead to cardiolipin deficiency and mitochondrial abnormalities. Patients most commonly develop an early-onset cardiomyopathy in infancy or fetal life. METHODS AND RESULTS: Knockdown of tafazzin (TAZKD) in a mouse model was induced from the start of gestation via a doxycycline-inducible shRNA transgenic approach. All liveborn TAZKD mice died within the neonatal period, and in vivo echocardiography revealed prenatal loss of TAZKD embryos at E12.5-14.5. TAZKD E13.5 embryos and newborn mice demonstrated significant tafazzin knockdown, and mass spectrometry analysis of hearts revealed abnormal cardiolipin profiles typical of Barth syndrome. Electron microscopy of TAZKD hearts demonstrated ultrastructural abnormalities in mitochondria at both E13.5 and newborn stages. Newborn TAZKD mice exhibited a significant reduction in total mitochondrial area, smaller size of individual mitochondria, reduced cristae density, and disruption of the normal parallel orientation between mitochondria and sarcomeres. Echocardiography of E13.5 and newborn TAZKD mice showed good systolic function, but early diastolic dysfunction was evident from an abnormal flow pattern in the dorsal aorta. Strikingly, histology of E13.5 and newborn TAZKD hearts showed myocardial thinning, hypertrabeculation and noncompaction, and defective ventricular septation. Altered cellular proliferation occurring within a narrow developmental window accompanied the myocardial hypertrabeculation-noncompaction. CONCLUSIONS: In this murine model, tafazzin deficiency leads to a unique developmental cardiomyopathy characterized by ventricular myocardial hypertrabeculation-noncompaction and early lethality. A central role of cardiolipin and mitochondrial functioning is strongly implicated in cardiomyocyte differentiation and myocardial patterning required for heart development. (J Am Heart Assoc. 2012;1:jah3-e000455 doi: 10.1161/JAHA.111.000455.)
format Online
Article
Text
id pubmed-3487377
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-34873772012-11-03 Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction Phoon, Colin K. L. Acehan, Devrim Schlame, Michael Stokes, David L. Edelman-Novemsky, Irit Yu, Dawen Xu, Yang Viswanathan, Nitya Ren, Mindong J Am Heart Assoc Original Research BACKGROUND: Barth syndrome is a rare, multisystem disorder caused by mutations in tafazzin that lead to cardiolipin deficiency and mitochondrial abnormalities. Patients most commonly develop an early-onset cardiomyopathy in infancy or fetal life. METHODS AND RESULTS: Knockdown of tafazzin (TAZKD) in a mouse model was induced from the start of gestation via a doxycycline-inducible shRNA transgenic approach. All liveborn TAZKD mice died within the neonatal period, and in vivo echocardiography revealed prenatal loss of TAZKD embryos at E12.5-14.5. TAZKD E13.5 embryos and newborn mice demonstrated significant tafazzin knockdown, and mass spectrometry analysis of hearts revealed abnormal cardiolipin profiles typical of Barth syndrome. Electron microscopy of TAZKD hearts demonstrated ultrastructural abnormalities in mitochondria at both E13.5 and newborn stages. Newborn TAZKD mice exhibited a significant reduction in total mitochondrial area, smaller size of individual mitochondria, reduced cristae density, and disruption of the normal parallel orientation between mitochondria and sarcomeres. Echocardiography of E13.5 and newborn TAZKD mice showed good systolic function, but early diastolic dysfunction was evident from an abnormal flow pattern in the dorsal aorta. Strikingly, histology of E13.5 and newborn TAZKD hearts showed myocardial thinning, hypertrabeculation and noncompaction, and defective ventricular septation. Altered cellular proliferation occurring within a narrow developmental window accompanied the myocardial hypertrabeculation-noncompaction. CONCLUSIONS: In this murine model, tafazzin deficiency leads to a unique developmental cardiomyopathy characterized by ventricular myocardial hypertrabeculation-noncompaction and early lethality. A central role of cardiolipin and mitochondrial functioning is strongly implicated in cardiomyocyte differentiation and myocardial patterning required for heart development. (J Am Heart Assoc. 2012;1:jah3-e000455 doi: 10.1161/JAHA.111.000455.) Blackwell Publishing Ltd 2012-04-24 /pmc/articles/PMC3487377/ /pubmed/23130124 http://dx.doi.org/10.1161/JAHA.111.000455 Text en © 2012 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. http://creativecommons.org/licenses/by/2.5/ This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Phoon, Colin K. L.
Acehan, Devrim
Schlame, Michael
Stokes, David L.
Edelman-Novemsky, Irit
Yu, Dawen
Xu, Yang
Viswanathan, Nitya
Ren, Mindong
Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction
title Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction
title_full Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction
title_fullStr Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction
title_full_unstemmed Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction
title_short Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction
title_sort tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487377/
https://www.ncbi.nlm.nih.gov/pubmed/23130124
http://dx.doi.org/10.1161/JAHA.111.000455
work_keys_str_mv AT phooncolinkl tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction
AT acehandevrim tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction
AT schlamemichael tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction
AT stokesdavidl tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction
AT edelmannovemskyirit tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction
AT yudawen tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction
AT xuyang tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction
AT viswanathannitya tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction
AT renmindong tafazzinknockdowninmiceleadstoadevelopmentalcardiomyopathywithearlydiastolicdysfunctionprecedingmyocardialnoncompaction